期刊论文详细信息
Diagnostic Pathology
KRAS, EGFR, PDGFR-α, KIT and COX-2 status in carcinoma showing thymus-like elements (CASTLE)
Ralf J Rieker6  Arndt Hartmann6  Peter Schirmacher1  Kurt W Schmid9  Nikolaus Neuhold3  Sören Schröder2  Michael A Kern1  Philipp Ströbel8  Jens Freitag4  Roland Penzel1  Petra Hufnagel5  Rupert Schupfner1,10  Lothar Veits7 
[1] Department of Pathology, University Hospital, INF 220/221, Heidelberg 69120, Germany;Institute of Pathology/Lademannbogen Laboratories, Lademannbogen 61-63, Hamburg 22339, Germany;Pathologisch-Bakteriologisches Institut, Kaiserin-Elisabeth-Spital, Huglgasse 1-3, Vienna 1150, Austria;General practitioner, Moselstraße 1, Oberbettringen 73529, Germany;Pathologielabor Zams, Klostergasse 1, Zams 6511, Austria;Department of Pathology, University Hospital Erlangen, Krankenhausstr. 10-12, Erlangen 91054, Germany;Institute of Pathology, Klinikum Bayreuth, Preuschwitzerstraße 101, Bayreuth 95445, Germany;Department of Pathology, University Hospital, Robert-Koch-Straße 40, Göttingen 37075, Germany;Department of Pathology and Neuropathology, University Hospital Essen, Hufelandstraße 55, Essen 45122, Germany;Clinic of Trauma and Reconstructive Surgery, Klinikum Bayreuth, Preuschwitzerstraße 101, Bayreuth 95445, Germany
关键词: Thyroid gland;    Immunohistochemistry;    Mutational analysis;    Thymic carcinoma;    CASTLE;   
Others  :  801362
DOI  :  10.1186/1746-1596-9-116
 received in 2013-12-03, accepted in 2014-05-15,  发布年份 2014
PDF
【 摘 要 】

Background

CASTLE (Carcinoma showing thymus-like elements) is a rare malignant neoplasm of the thyroid resembling lymphoepithelioma-like and squamous cell carcinoma of the thymus with different biological behaviour and a better prognosis than anaplastic carcinoma of the thyroid.

Methods

We retrospectively investigated 6 cases of this very rare neoplasm in order to investigate the mutational status of KRAS, EGFR, PDGFR-α and KIT, as well as the immunohistochemical expression pattern of CD117, EGFR and COX-2, and possibly find new therapeutic targets.

Results

Diagnosis was confirmed by a moderate to strong expression of CD5, CD117 and CK5/6, whereas thyroglobulin, calcitonin and TTF-1 were negative in all cases. Tumors were also positive for COX-2 and in nearly all cases for EGFR. In four cases single nucleotide polymorphisms (SNPs) could be detected in exon 12 of the PDGFR-α gene (rs1873778), in three cases SNPs were found in exon 20 of the EGFR gene (rs1050171). No mutations were found in the KIT and KRAS gene.

Conclusions

All tumors showed a COX-2 expression as well as an EGFR expression except for one case and a wild-type KRAS status. No activating mutations in the EGFR, KIT and PDGFR-α gene could be detected. Our data may indicate a potential for targeted therapies, but if these therapeutic strategies are of benefit in CASTLE remains to be determined.

Virtual Slides

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1658499296115016 webcite

【 授权许可】

   
2014 Veits et al.; licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20140708005213788.pdf 1678KB PDF download
Figure 2. 53KB Image download
Figure 1. 248KB Image download
【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】
  • [1]Miyauchi A, Kuma K, Matsuzuka F, Matsubayashi S, Kobayashi A, Tamai H, Katayama S: Intrathyroidal epithelial thymoma: an entity distinct from squamous cell carcinoma of the thyroid. World J Surg 1985, 9:128-135.
  • [2]Chan JK, Rosai J: Tumors of the neck showing thymic or related branchial pouch differentiation: a unifying concept. Hum Pathol 1991, 22:349-367.
  • [3]Cheuk W, Chan JKC, Dorfmann DM, Giordano T: Spindle Cell Tumour With Thymus-Like Differentiation. In World Health Organization Classification of Tumours. Tumours of Endocrine Organs. Edited by DeLellis RA, Lloyd RV, Heitz PU, Eng C. Lyon: IARC Press; 2004:96-97.
  • [4]Ito Y, Miyauchi A, Nakamura Y, Miya A, Kobayashi K, Kakudo K: Intrathyroid Epithelial Thymoma/Carcinoma Showing Thymus-Like Differentiation (CASTLE): Its Clinicopathological Characteristics. In Recent Advances in Thyroid Cancer Research. Kerala: Transworld Research Network; 2006:151-164.
  • [5]Carcangiu ML, Steeper T, Zampi G, Rosai J: Anaplastic thyroid carcinoma: a study of 70 cases. Am J Clin Pathol 1985, 83:135-158.
  • [6]Alexiev BA, Drachenberg CB, Burke AP: Thymomas: a cytological and immunohistochemical study, with emphasis on lymphoid and neuroendocrine markers. Diagn Pathol 2007, 2:13.
  • [7]Veits L, Mechtersheimer G, Steger C, Freitag J, Mikuz G, Schmid KW, Hofmann W, Schirmacher P, Hartmann A, Rieker RJ: Chromosomal imbalances in carcinoma showing thymus-like elements (CASTLE). Virchows Arch 2011, 459:221-226.
  • [8]Henley JD, Cummings OW, Loehrer EJ Sr: Tyrosin kinase receptor expression in thymomas. J Cancer Res Clin Oncol 2004, 130:222-224.
  • [9]Giaccone G: Treatment of malignant thymoma. Curr Opin Oncol 2005, 17:140-146.
  • [10]Ströbel P, Marx A, Zettl A, Muller-Hermelink HK: Thymoma and thymic carcinoma: an update of the WHO classification 2004. Surg 2004, 35:805-811.
  • [11]Rieker RJ, Joos S, Mechtersheimer G, Blaeker H, Schnabel PA, Morresi-Hauf A, Hecker E, Thomas M, Dienemann H, Schirmacher P, Kern MA: COX-2 upregulation in thymomas and thymic carcinomas. Int J Cancer 2006, 119:2063-2070.
  • [12]Rieker RJ, Schnabel PA, Mechtersheimer G, Thomas M, Dienemann H, Schirmacher P, Kern MA: COX-2 expression in thymomas and thymic carcinomas: a novel therapeutic target? Diagn Pathol 2007, 2(Suppl 1):S3.
  • [13]Ma Y, Li Q, Cui W, Miao N, Liu X, Zhang W, Zhang C, Wang J: Expression of c-Jun, p73, Casp9, and N-ras in thymic epithelial tumors: relationship with the current WHO classification systems. Diagn Pathol 2012, 7:120.
  • [14]Pan CC, Chen PC, Chiang H: KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol 2004, 20:375-381.
  • [15]Ströbel P, Hartmann M, Jakob A, Mikesch K, Brink I, Dirnhofer S, Marx A: Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 2004, 350:2625-2626.
  • [16]Buti S, Donini M, Sergio P, Garagnani L, Schirosi L, Passalacqua R, Rossi G: Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma. J Clin Oncol 2011, 29:803-805.
  • [17]Girard N: Thymic tumors: relevant molecular data in the clinic. J Thorac Oncol 2010, 5:291-295.
  • [18]Pescarmona E, Pisacane A, Pignatelli E, Baroni CD: Expression of epidermal and nerve growth factor receptors in human thymus and thymomas. Histopathology 1993, 23:39-44.
  • [19]Gilhus NE, Jones M, Turley H, Gatter KC, Nagvekar N, Newsom-Davis J, Willcox N: Oncogene proteins and proliferation antigens in thymomas: increased expression of epidermal growth factor receptor and Ki67 antigen. J Clin Pathol 1995, 48:447-455.
  • [20]Henley JD, Koukoulis GK, Loehrer PJ Sr: Epidermal growth factor receptor expression in invasive thymoma. J Cancer Res Clin Oncol 2002, 128:167-170.
  • [21]Suzuki E, Sasaki H, Kawano O, Endo K, Haneda H, Yukiue H, Kobayashi Y, Yano M, Fujii Y: Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. Jpn J Clin Oncol 2006, 36:351-356.
  • [22]Meister M, Schirmacher P, Dienemann H, Mechtersheimer G, Schnabel PA, Kern MA, Herpel E, Xu EC, Muley T, Thomas M, Rieker RJ: Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas. Cancer Lett 2007, 248:186-191.
  • [23]Yoh K, Nishiwaki Y, Ishii G, Goto K, Kubota K, Ohmatsu H, Niho S, Nagai K, Saijo N: Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer 2008, 62:316-320.
  • [24]Aisner SC, Dahlberg S, Hameed MR, Ettinger DS, Schiller JH, Johnson DH, Aisner J, Loehrer PJ: Epidermal growth factor receptor, C-Kit, and Her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Oncology Group Study. J Thorac Oncol 2010, 5:885-892.
  • [25]Girard N, Shen R, Guo T, Zakowski MF, Heguy A, Riely GJ, Huang J, Lau C, Lash AE, Ladanyi M, Viale A, Antonescu CR, Travis WD, Rusch VW, Kris MG, Pao W: Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res 2009, 15:6790-6799.
  • [26]Yamaguchi H, Soda H, Kitazaki T, Tsukamoto K, Hayashi T, Kohno S: Thymic carcinoma with epidermal growth factor receptor gene mutations. Lung Cancer 2006, 52:261-262.
  • [27]Janne PA, Engelman JA, Johnson BE: Epidermal growth factor receptor mutations in nonsmall-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 2005, 23:3227-3234.
  • [28]Kurup A, Burns M, Dropcho S, Pao W, Loehrer PJ: Phase II study of gefitinib treatment in advanced thymic malignancies [abstract]. J Clin Oncol 2005, 23:s7068.
  • [29]Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R: A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003, 348:883-890.
  • [30]Malka D, Pacault V, De Baere T, Ducreux M, Boige V: Antitumoral effect of celecoxib in hepatocellular carcinoma. J Clin Oncol 2005, 23:4805-4806.
  • [31]Kulkarni S, Rader JS, Zhang F, Liapis H, Koki AT, Masferrer JL, Subbaramaiah K, Dannenberg AJ: Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 2001, 7:429-434.
  • [32]Pai R, Soreghan B, Szabo IL, Pavelka MP, Baater D, Tarnawski AS: Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002, 8:289-293.
  • [33]Pai R, NakamuraT MWS, Tarnawski AS: Prostaglandins promote colon cancer invasion; signalling by cross-talk between two distinct growth factor receptors. FASEB J 2003, 17:1640-1647.
  • [34]Huh YH, Kim SH, Kim SJ, Chun JS: Differentiation status-dependent regulation of cyclooxygenase-2 expression and prostaglandin E2 production by epidermal growth factor via mitogen-activated protein kinase in articular. J Biol Chem 2003, 278:9691-9697.
  • [35]Ströbel P, Bargou R, Wolff A, Spitzer D, Manegold C, Dimitrakopoulou-Strauss A, Strauss L, Sauer C, Mayer F, Hohenberger P, Marx A: Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br J Cancer 2010, 103:196-200.
  文献评价指标  
  下载次数:5次 浏览次数:6次